Anika Therapeutics (ANIK) Research & Development (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Research & Development data on file, last reported at $6.7 million in Q1 2026.

• Research & Development for Q1 2026 came in at $6.7 million, up 10.79% year-over-year; the trailing twelve-month figure through Mar 2026 was $26.4 million (up 4.88% YoY), and the FY2025 annual result was $25.8 million, up 0.88% from the prior year.
• Research & Development climbed to $6.7 million in Q1 2026 per ANIK's latest filing, from $6.5 million in the prior quarter.
• Over five years, Research & Development peaked at $8.9 million in Q2 2023 and troughed at -$3.3 million in Q4 2023.
• A 5-year average of $5.8 million and a median of $6.5 million in 2024 frame the typical range for Research & Development.
• The sharpest annual moves came in 2022 and 2024: Research & Development tumbled 135.2% in 2022, then soared 294.7% in 2024.
• A 5-year view of Research & Development shows it stood at -$2.1 million in 2022, then slumped by 58.24% to -$3.3 million in 2023, then soared by 294.7% to $6.5 million in 2024, then dropped by 0.85% to $6.5 million in 2025, then rose by 4.05% to $6.7 million in 2026.
• Business Quant data shows ANIK's Research & Development at $6.7 million in Q1 2026, $6.5 million in Q4 2025, and $6.9 million in Q3 2025.